Insilico Medicine used artificial intelligence to develop rentosertib, a drug for chronic lung disease, and early trial data suggests it may also reduce biological markers of aging. The findings come with major caveats: the sample size was small, the drug hasn't been tested in healthy people, and the "aging clocks" used to measure results are scientifically debated.

• Rentosertib reduced biological aging markers across six different AI-based "aging clocks" in a clinical trial, according to results published in Nature Biotechnology.
• The drug was originally developed for idiopathic pulmonary fibrosis (IPF) and has only been tested in sick patients, not healthy ones, so anti-aging claims remain speculative.
• The study has significant limitations: small sample size, unproven reliability of aging clock measurements, and the drug is still years away from regulatory approval even for its primary lung disease indication.

China is running seven clinical trials using chemogenetics, a technique that lets doctors control specific neurons with designer drugs, but the current approach uses clozapine at ultra-low doses instead of truly inert compounds, raising questions about precision and safety. The technology is sound for treating epilepsy and Parkinson's disease, though next-generation versions could be significantly better.

• Seven ongoing trials in China are testing chemogenetics for epilepsy, Parkinson's disease, and pain by injecting modified genes into the brain that make neurons respond to clozapine taken orally—affecting roughly 10 patients so far.
• Clozapine is used at 1% of the antipsychotic dose in Parkinson's trials and similarly low in epilepsy trials, minimizing off-target effects, but it's still not truly inert and requires long-term monitoring for rare idiosyncratic reactions like agranulocytosis.
• Current trials use hM4Di, which is only 2 amino acids different from the native human M4 receptor, reducing immune rejection risk, but genuinely inert alternatives like DCZ exist and could improve precision in future versions—they just haven't been approved for human use yet.

A new $500 million fund backed by Stripe, Anthropic and others will support drugs and air filtration tech aimed at preventing colds, flu and other respiratory viruses. It plans to shepherd at least two therapies through Phase I/II trials and pilot air-cleaning systems in offices to de-risk them for larger investors.

• A $500M fund called Intercept, backed by Stripe and Anthropic, aims to push antiviral drugs and air-filtration tech to eliminate colds and flu.
• Strategy is to fund the risky early trials (Phase I/II) for at least two drug candidates, then hand off to big pharma for expensive Phase III trials.
• It's also funding real-world pilot tests of HEPA/UV air-cleaning systems at companies like Warby Parker, Mastercard, and JPMorgan.
• Experts warn $500M is likely insufficient, since Phase I/II trials alone cost $20-30M each and Phase III costs far more.

The article argues that AI will revolutionize drug discovery long before it can streamline clinical development, creating an abundance of candidate molecules but leaving patient trials as the main constraint. As discovery becomes commoditized and more assets target the same biology, real value will hinge on predictive toxicity, clinical efficacy, and strategic trial design.

• Drug candidate pipelines have doubled in the past decade but novel FDA approvals stayed flat at ~50/year, proving clinical development—not discovery—is the real bottleneck.
• Preclinical assets license for tens of millions, but value jumps to hundreds of millions or low-billions post-Phase 2 proof of concept—a premium set to shrink as AI floods the pipeline with candidates.
• Competition per target is already intense (100+ programs on targets like PD-1/GLP-1) and could double or triple by 2030, making individual molecules less rare and pushing investors to demand better translational data and trial design.
• AI excels at data-rich, fast-feedback problems (virtual screening, protein folding) but struggles with messy, high-variability clinical questions (endpoint selection, immune response prediction, adaptive trials)—so real value will shift to whoever masters those still-slow areas.

Science Corp, led by Max Hodak, will test its biohybrid brain sensor in humans under Dr. Murat Günel’s guidance. The implant, which sits on the cortex inside the skull and uses 520 electrodes, will first be tried without neurons in patients already undergoing craniotomy. The long-term goal is to integrate lab-grown neurons with electronics to treat stroke, spinal injuries and Parkinson’s.

• Science Corp is placing its first biohybrid brain sensor (520 electrodes, pea-sized) in humans, led by Yale neurosurgeon Dr. Murat Günel, without seeking FDA approval by piggybacking on routine craniotomies.
• Initial trials will test only the electronic sensor without lab-grown neurons, with the neuron-integration technology planned for later stages.
• The company raised $230 million at a $1.5 billion valuation, and its more advanced product PRIMA is awaiting European approval to restore vision in macular degeneration patients.
• Günel argues coupling electronics with transplanted neurons could protect neural circuits and slow diseases like Parkinson's in ways pure electrical stimulation cannot, though he calls a 2027 human trial timeline ambitious.

The FDA plans to reduce the number of required pivotal trials in Phase 3 clinical studies from two to one, aiming to streamline drug development. While this may benefit smaller biotech companies, the impact will vary by disease, as some conditions may still necessitate more trials to ensure safety and efficacy.

• FDA is shifting the default Phase 3 requirement from two pivotal trials to one, potentially cutting years and money off the $2.6 billion, 10-15 year drug development process.
• The impact will be uneven: urgent diseases like ALS could benefit from faster single-trial approval, while high-placebo-response conditions like pain may struggle to prove efficacy with just one study.
• Smaller biotechs with limited funding but multiple drugs in development stand to gain the most from reduced trial requirements.
• FDA plans to offset reduced pre-approval testing with continued postmarket surveillance and new tools like AI and real-world data to maintain safety and precision.

The FDA plans to allow drug approvals based on a single clinical trial instead of the traditional two. Commissioner Marty Makary stated that this change aims to streamline the approval process while maintaining safety and efficacy standards. Some exceptions will still apply, where two trials may be required.

• FDA will now generally accept a single clinical trial for drug approval instead of the traditional two
• Two trials will still be required in certain (unspecified) cases
• Makary argues a well-designed, controlled single trial can match the statistical power of two trials
• Many drugmakers were already submitting only one pivotal trial, so the policy formalizes existing practice

Claude for Healthcare is now available, providing HIPAA-compliant tools for healthcare providers and patients to improve medical processes such as prior authorizations and claims appeals. Additionally, Claude for Life Sciences has expanded its capabilities to better support clinical trial operations and regulatory submissions. These advancements aim to streamline healthcare tasks and enhance the quality of patient care.

• Claude for Healthcare launches with HIPAA-compliant tools plus connectors to CMS Coverage Database, ICD-10, and the NPI Registry for faster data retrieval and report generation
• New Agent Skills target prior authorization reviews and interoperability, letting organizations customize workflows to speed approvals and support claims appeals
• Opus 4.5's improved medical/scientific performance extends Claude's use into ambient scribing, clinical decision support, and personal health data summarization for individual users
• Claude for Life Sciences adds integrations with Medidata and ClinicalTrials.gov to support clinical trial patient recruitment, protocol design, and access to historical trial data

Biomedical progress in therapeutics has been hindered despite advances in basic science, a trend known as Eroom's Law. The Clinical Trial Abundance Project aims to enhance the efficiency and informativeness of clinical trials, arguing that learning from both successes and failures is crucial for developing new therapies, as exemplified by the evolution of CAR-T cell therapies.

• Inflation-adjusted drug development costs have doubled roughly every 9 years since the 1950s (Eroom's Law), even as basic science has advanced.
• Clinical trials shouldn't just validate existing hypotheses—they should function as an active discovery engine, with failures generating insights that improve subsequent trial designs.
• CAR-T therapy's eventual success (e.g., Kymriah's FDA approval via the ELIANA trial) came only after nearly two decades of iterative trial failures that progressively refined understanding of T cell responses.
• Making trials faster and more efficient isn't in tension with generating better drug hypotheses—the two goals are complementary and can reinforce each other in a positive feedback loop.